Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $38.2 million.

  • Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) rose 10.97% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 10.97%. This contributed to the annual value of $38.2 million for FY2024, which is 15.47% up from last year.
  • As of FY2024, Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $38.2 million, which was up 15.47% from $33.1 million recorded in FY2023.
  • Tarsus Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $38.2 million for FY2024, and its period low was $20.3 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $32.7 million, with a median of $33.1 million in 2023.
  • Data for Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 28.99% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Tarsus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $20.3 million in 2020, then increased by 1.75% to $20.7 million in 2021, then increased by 28.99% to $26.7 million in 2022, then grew by 24.12% to $33.1 million in 2023, then climbed by 15.47% to $38.2 million in 2024.